This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful. Check our privacy policy here.
In: OST-122
February 2020
Oncostellae received regulatory approval to start a proof of concept study with OST-122 in patients with ulcerative colitis
febrero 21, 2020
Oncostellae has received permission from the regulator to start a Phase 2a study with OST-122 in patients suffering from ulcerative colitis….
Read More
May 2019
OST-122 has successfully completed a Phase 1b trial in HV and has proved to be GI-restricted and well tolerated up to 1200 mg after multiple dosing
febrero 20, 2020
Following a successful randomized, double-blind, placebo-controlled Phase 1a clinical trial in healthy volunteers which was carried out at the Sant Pau…
Read More